ahlam1399
05-29-2015, 11:38 PM
Genetic glitch can predict response to new class of cancer *****
CHICAGO (Reuters) - Patients with colon and other cancers who have a specific defect in genes needed for DNA repair are far more likely to respond to a new class of ***** such as Merck & Co's Keytruda, which enlist the immune system to attack tumors, a new study has shown.http://i2.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/46c4a344/sc/14/mf.gif?resize=1%2C1
http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=iDnHQ1ffHz8:4P2olBaXbL8:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=iDnHQ1ffHz8:4P2olBaXbL8:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=iDnHQ1ffHz8:4P2olBaXbL8:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=iDnHQ1ffHz8:4P2olBaXbL8:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=iDnHQ1ffHz8:4P2olBaXbL8:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/iDnHQ1ffHz8
CHICAGO (Reuters) - Patients with colon and other cancers who have a specific defect in genes needed for DNA repair are far more likely to respond to a new class of ***** such as Merck & Co's Keytruda, which enlist the immune system to attack tumors, a new study has shown.http://i2.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/46c4a344/sc/14/mf.gif?resize=1%2C1
http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=iDnHQ1ffHz8:4P2olBaXbL8:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=iDnHQ1ffHz8:4P2olBaXbL8:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=iDnHQ1ffHz8:4P2olBaXbL8:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=iDnHQ1ffHz8:4P2olBaXbL8:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=iDnHQ1ffHz8:4P2olBaXbL8:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/iDnHQ1ffHz8